MyJSCAI

The official scientific journal of @SCAI.

EIC: Alexandra Lansky, MD, MSCAI

[MyJSCAI @MyJSCAI]

🚨Exciting News! #JSCAI is accepted for PubMed Central Indexing!🎉

Read @AlexandraLansky's editorial:
➡️https://t.co/eQVlmXEXYV

📢This significant milestone boosts our authors' visibility, citation rates, and recognition by making all articles more accessible to researchers and practitioners.

♥️Thank you to our Editors, Authors, Reviewers, and everyone for their unwavering support in making this possible. @SCAI

[Michael Megaly @MichaelMegalyMD]

Among the criticisms of #CTO #PCI is the higher risk compared to regular PCI procedures. This perception stems from the procedure's higher complexity.

The unmeasured factor is that CTO PCI is usually performed by operators who can identify and treat possible complications faster and have the awareness to prevent problems or manage them.

Our study from the National Trinetix database @MyJSCAI, led by @AdhamGR97 and @MohamedDomaa, compared 30-day outcomes between CTO PCI and ELECTIVE (non-MI) non-CTO PCI, and also trended outcomes over three recent periods (2014-2017, 2018-2021, 2022-2025).

Our major findings are as follows

1-CTO PCI risk of pericardiocentesis was higher than non-CTO PCI (0.2% vs 0.09%) but remains very small at 0.2%

2-CABG after CTO PCI was higher than non-CTO PCI; we could not determine the cause, but it was mostly related to failure and the need for revascularization rather than complications.
Also, the trend of CABG after CTO PCI has been decreasing.

3-Finally, none of this led to adverse outcomes, as there was absolutely no difference in mortality between the two groups.

In the hands of experienced operators, CTO PCI can be safe and effective.

https://t.co/7Acp7f60Eq

#CardioX #ACCFIT

[TCTMD @TCTMD]

Death tied to aortic stenosis are declining but progress has not been equal.
Analysis of US data from 1999-2024 shows persistent disparities in AS-related mortality by demographic and geographic groups. @MyJSCAI
Read more: https://t.co/SseMFxuCis

[BIDMC Smith Center @SmithBIDMC]

Featured in @CardioBusiness : Helena Smith and @EricSecemskyMD’s @MyJSCAI editorial describes the potential value of optical coherence tomography (OCT) in below-the-knee endovascular interventions. 🔗 Read the full editorial here: https://t.co/A4Wz4EnmX3

[MyJSCAI @MyJSCAI]

🆕📢One-Year Outcomes from the FORWARD #PAD IDE and Mini S feasibility studies of the novel Javelin #IVL Catheter

➡️https://t.co/5WYhJ0JjFi

@JDCorlMD @nicolas_shammas @PeterSoukas

[UCLA Radiology @RadiologyUcla]

High-risk pulmonary embolism still carried just 67.8% one-year survival in real-world data. In @MyJSCAI, @RadiologyUcla's Dr. @JonnyMoriarty & collaborators map PE care across 54 US sites and 11,612 patients. https://t.co/P2kQUCpvrO

[Giuseppe Biondi-Zoccai @gbiondizoccai]

Evaluation and Treatment of Myocardial Bridging by Clinical Phenotype https://t.co/ioT6E9dlrE @MyJSCAI @MortonKern

[MyJSCAI @MyJSCAI]

🆕📖Economic analysis based on the #ZPEERLESS RCT shows large-bore mechanical thrombectomy is cost-effective compared to catheter-directed thrombolytics for intermediate-risk #PE, providing lifetime cost savings & improved #QoL.

➡️ https://t.co/JUwWck8dhj

@SamHorrMD @keithppereira @jaygirimd @SameerKhandhar @AzeneMD @wissamj123 @carin_gonsalves @StefanStortecky

#LBMT #CostEffective #JSCAI #PEERLESS

[MyJSCAI @MyJSCAI]

📖Improving #PCI safety & efficiency through cath lab #CQI implementation: #AKI ↓ (14.3%→9.7%), Hgb drop ↓ (0.65→0.54 g/dL), &same-day discharge ↑ (13.0%→24.7%).

➡️https://t.co/Tp3XJlezNA

#RadialFirst #samedaydischarge

@hsuradi

[BIDMC Smith Center @SmithBIDMC]

Featured in @CardioBusiness : Helena Smith and @EricSecemskyMD’s @MyJSCAI editorial describes the potential value of optical coherence tomography (OCT) in below-the-knee endovascular interventions. 🔗 Read the full editorial here: https://t.co/A4Wz4EnmX3

[Christopher Chinnatambi MD @CChinnatambi]

🚨 Grateful to share that our new paper on DAPT duration after acute coronary syndrome has been published in Cardiovascular Revascularization Medicine!

📈 Across 7 RCTs and 17,515 ACS patients, 3-month DAPT followed by monotherapy performed just as well as 12-month therapy for ischemic protection, while meaningfully reducing bleeding.

✅ Key findings:

MACCE: 5.6% vs 5.7% (RR 0.96; 95% CI 0.79–1.17) — no difference
Clinically relevant bleeding: 3.0% vs 4.9% (RR 0.62; 95% CI 0.50–0.76) — a 38% relative risk reduction, NNT of 52
Net adverse clinical events: 7.9% vs 9.7% (RR 0.81; 95% CI 0.66–1.00)

💡 Trial sequential analysis found:

Conclusive evidence of futility for added ischemic benefit with longer DAPT
Conclusive evidence of benefit for bleeding reduction with abbreviated DAPT

🙏 Grateful to Drs. @IbebuoguMD , @DrDrewKleinPHI , @tristonsmithmd , and Sudhir Mungee for their mentorship and guidance throughout this project, and to my co-authors for their contributions! [@louise_orth ,@sahmIbrah]

[Ravi Thakker, MD @rthakker92]

Which sheath do you utilize for single-access PCI?

In our recent novel study @MyJSCAI, we characterize the mechanics of commonly utilized sheaths for single-access PCI including @jjmt_heartrecov #Abiomed Companion Sheath.

https://t.co/YHCfMOJU3Q

[SCAI @SCAI]

🫀 Explore the latest research and expert perspectives shaping #CardiogenicShock care in a new @MyJSCAI Editor-in-Chief curated collection.

Dive into advances in mechanical circulatory support, emerging treatment strategies, and innovations in complex care.

Explore the collection ➡️ https://t.co/NyIa0T5Fvc

#InterventionalCardiology @AlexandraLansky

[SCAI @SCAI]

📰 The newest issue of @MyJSCAI is out now!

Stay current with the latest #InterventionalCardiology research, clinical insights, and emerging evidence from experts around the world—all fully Gold Open Access.

Explore the latest issue ➡️ https://t.co/f968e7eGs4

[mohammad al-sayaideh @msayaydeh]

Excited to share our new review in @MyJSCAI! 🫀

Transcatheter Aortic Valve Migration and Embolization During TAVR: a contemporary management review with a practical bailout algorithm.

#TAVR #StructuralHeart #InterventionalCardiology

https://t.co/3SrB8VF6aB

[UCLA Radiology @RadiologyUcla]

In @MyJSCAI, @RadiologyUcla's Dr. @JonnyMoriarty & collaborators profile 11,612 pulmonary embolism patients across 54 US sites, most at intermediate risk, in one of the largest real-world PE datasets yet. https://t.co/P2kQUCpvrO

[SCAI @SCAI]

🪨 Explore the latest Editor-in-Chief Curated Collection by @AlexandraLansky in @MyJSCAI Intravascular Lithotripsy (IVL): Advancing Treatment of Calcified Lesions.

From procedural strategies to the latest clinical evidence, this collection highlights key studies and expert insights shaping the evolving role of IVL in contemporary practice.

Explore the collection ➡️ https://t.co/e2YfrcwoBX

#InterventionalCardiology

[TCTMD @TCTMD]

New data highlights geographical challenges in STEMI patient treatment, noting that a pharmacoinvasive strategy still remains an integral part of STEMI care in rural areas. Eric Rothstein urges a rethinking of the system to improve outcomes.
https://t.co/HFAMPedrQG @MyJSCAI

[MIЯVΛƬ #IC ༄ ｡° @mirvatalasnag]

@MyJSCAI
MINOCA excellent work led by @ZainabDakhil2

Co-authors: #HasanFarhan @JGrapsa

🌍 Global disparities exist in the diagnostic evaluation of MINOCA
💰 Economic factors are the most consistent determinants of advanced diagnostic modality use
🧲 Pressing need for standardized evaluation pathways across diverse health care settings

https://t.co/T8K636ASCW

[MyJSCAI @MyJSCAI]

💡 New from #JSCAI: Topical Collections make it easier to find the latest research, reviews, & expert perspectives on key areas in #IC. Explore now: https://t.co/OUySSDQmTE

💠 #CardiogenicShock
💠 #PulmonaryEmbolism
💠 #IVL
💠 #Radiation

[MyJSCAI @MyJSCAI]

📚New case series: Catheter-directed recombinant tissue plasminogen activator successfully resolved aortic root and/or coronary thrombosis in 3 of 4 single-ventricle patients, with no procedural complications.

➡️ https://t.co/Gcka5Mi8Uh

@amrmatoq